XYZ-REALITY
16.4.2024 14:02:02 CEST | Business Wire | Press release
XYZ Reality, the leading engineering grade augmented reality (AR) platform for data center and mission critical construction, is proud to announce the appointment of data center industry veterans Christian Belady and Brian Mattson as Strategic Advisors. With their extensive experience and innovative vision, they will help guide XYZ Reality in enhancing its data center construction solution and product roadmap.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240416398782/en/
Christian Belady (Photo: Business Wire)
Christian Belady, recognized as one of the "5 People who changed the data center" industry, brings a wealth of expertise in managing data center and infrastructure development at a global scale. Formerly Vice President and Distinguished Engineer at Microsoft, Belady developed one of the largest data center footprints in the world. Notably, during his tenure at Hewlett Packard, he was the innovator behind the Power Usage Effectiveness (PUE) metric. His expertise will prove invaluable to XYZ Reality's mission of building it right first time, offering crucial support in product development and sharing invaluable insights and expertise garnered from years of experience in the data center industry.
“I am thrilled to join XYZ Reality as a Strategic Advisor,” said Christian Belady. “At a time when speed to market is paramount, the company’s approach and cutting-edge technology to transforming data center construction and delivery is impressive, and I am eager to contribute to its success with our combined experience and knowledge.”
Brian Mattson brings over 40 years of experience leading large-scale global engineering and construction programs in the semiconductor and data center industries. Prior to joining XYZ Reality, Mattson served in leadership roles at Google, NTT Global Data Centers Americas, and Microsoft. His leadership at Google and Microsoft in global construction and infrastructure supply chain will contribute significantly to XYZ Reality’s growth.
"We are delighted to welcome Christian Belady and Brian Mattson to XYZ Reality as Strategic Advisors," said David Mitchell, Founder & CEO of XYZ Reality. "Their passion, expertise and innovative track record are crucial as we transform the data center industry with our Platform. This collaboration will further enhance our real-time project controls, enabling a proactive approach to construction. Their insights in the mission critical space will streamline processes and boost efficiency as we pioneer proactive solutions in this field.”
Notes to Editor
XYZ Reality is a leading developer of construction technology solutions that give owners and contractors an accurate and objective way to manage and deliver projects. Combining its Engineering Grade AR™ technology and comprehensive Project Controls solution, XYZ gives construction teams the ability to accurately build from holograms of 3D models, and proactively manage their projects with objective real-time insights. This is a revolutionary move away from a reliance on 2D drawings and subjective, out of date data, towards a future where accuracy means each project is built right, first time. The largest developers have implemented XYZ on projects totaling over $10 billion. XYZ is headquartered in London, England with offices around the globe. For more information, visit www.xyzreality.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240416398782/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release
The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom